- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01522950
A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function (EVIDENCE)
A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Rasmussen Disease Score (RDS) test panel is the chosen methodology for this study. The 10 parameters of the RDS were selected because of their ability to quantify early structural and functional abnormalities in the vasculature and left ventricle which appear long before cardiovascular disease is present.
The RDS tests include: large and small artery elasticity (measured by pulse contour analysis), resting blood pressure, mild treadmill exercise test, carotid IMT, left ventricle mass, ECG, retinal vasculature evaluation, as well as quantification of serum NT-proBNP, and microalbuminuria. Quantitative results from these tests are converted into categorical classifications based on values stratified by age and gender when appropriate. The categorical data is scored as follows: normal = 0 points, borderline = 1 point, abnormal = 2 points. Point values from all parameters are summed to create the RDS, with values ranging from 0-20. Scores of 0-2 are classified as normal, 3-5 as early disease, and 6+ as advanced disease. Previous research has shown that the RDS is a powerful predictor of future cardiovascular events.
The small artery elasticity (C2) parameter is of particular interest as it is responsive to changes in NO levels and is an effective and reliable predictor of future hypertension and other cardiovascular events. Changes in C2 will serve as the primary outcome of this study. Similar studies using anti-hypertensive or lipid-lowering interventions have found significant improvements in C2 values.
Brachial artery flow-mediated dilation (FMD) measurements will also be measured as an index of endothelial function, although this method appears to be less sensitive to functional changes related to NO bioavailability than C2. Utilizing both FMD and C2 will allow comparison with previous studies and take advantage of a large sample size to further examine the relative sensitivity of each method for reliably measuring endothelial dysfunction.
The duration of intervention for this study is 9 months which is the minimum time to adequately detect improvement in left ventricle (LV) mass values. LV mass measurements are a critical component of a comprehensive assessment of cardiovascular health and have improved within this temporal window as a result of anti-hypertensive intervention.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- borderline blood pressure (120-145/80-90 mm Hg);
- borderline or abnormal small artery elasticity (C2) as measured by pulse contour analysis;
- treatment-naive for all blood pressure medications including diuretics for at least 30 days prior to baseline visit;
- able to walk on a treadmill for 3 minutes;
- female patients with reproductive potential must use an approved contraceptive method if appropriate (for example, intrauterine device [IUD], birth control pills, or barrier device during and for 1 month after the last dose of study drug;
- voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
Exclusion Criteria:
- history of intolerance to beta-blockers or clear contraindications to their use; current pharmaceutical treatment of blood pressure;
- known history of cardiovascular disease (myocardial infarction, coronary artery bypass graft, unstable angina, uncontrolled arrhythmias, stroke, etc.);
- known history of diabetes; known history of hepatic, renal or gastrointestinal disorder;
- known history of any illness that may cause additional risk (as determined by study investigator);
- pregnant or lactating women [when used during pregnancy, beta-blockers may cause fetal harm];
- participation in a concomitant clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nebivolol
5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months.
Dose may be returned to initiation levels if side effects occur.
|
5 mg daily or 10 mg daily
|
Active Comparator: Atenolol
25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months.
Dose may be returned to initiation levels if side effects occur.
|
25 mg daily or 50 mg daily
|
Placebo Comparator: Placebo
Continue for 1 month; dose titration to "high dose" placebo, continue for 8 months.
Dose may be returned to initiation levels if side effects occur.
|
one tablet daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Small Artery Elasticity
Time Frame: baseline, 9 months
|
Change in small artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.
|
baseline, 9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Large Artery Elasticity
Time Frame: baseline, 9 months
|
Change in large artery elasticity (a marker for endothelial function) from baseline to 9 months after intervention initiation.
|
baseline, 9 months
|
Change in Systolic Blood Pressure
Time Frame: baseline, 9 months
|
Change in systolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.
|
baseline, 9 months
|
Change in Diastolic Blood Pressure
Time Frame: baseline, 9 months
|
Change in diastolic blood pressure as measured by sphygmomanometer from baseline to 9 months after intervention initiation.
|
baseline, 9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jay N Cohn, MD, University of Minnesota Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Adrenergic beta-1 Receptor Agonists
- Nebivolol
- Atenolol
Other Study ID Numbers
- CV-2014-20226
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Nebivolol
-
Forest LaboratoriesCompletedStage 2 Hypertension | Stage 1 HypertensionUnited States
-
Bio-innova Co., LtdNot yet recruitingHealthy Subjects
-
University of AbujaMicronova Pharmaceuticals Ind LtdCompleted
-
East Coast Institute for ResearchCompletedHypertension | Female Sexual DysfunctionUnited States
-
Ain Shams UniversityRecruiting
-
Forest LaboratoriesCompletedStage 2 Diastolic HypertensionUnited States, Puerto Rico
-
Jack RubinsteinForest LaboratoriesTerminated
-
Forest LaboratoriesCompletedHypertensionUnited States
-
Menarini International Operations Luxembourg SACompleted
-
Betaliq, Inc.Trial Runners, LLC; Summit Analytical, LLCCompletedOcular Hypertension | Open-Angle GlaucomaUnited States